This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Indolfi, C. Articles by Chiariello, M. Search for Related Content PubMed PubMed Citation Articles by Indolfi, C. Articles by Chiariello, M. Related Collections Restenosis Cell signalling/signal transduction Smooth muscle proliferation and differentiation Type 1 diabetes Type 2 diabetes

(Circulation. 2001;103:2980.)
© 2001 American Heart Association, Inc.

Basic Science Reports

Effects of Balloon Injury on Neointimal Hyperplasia in Streptozotocin-Induced Diabetes and in Hyperinsulinemic Nondiabetic Pancreatic Islet–Transplanted Rats

Ciro Indolfi, MD; Daniele Torella, MD; Luigi Cavuto, MD; Alberto M. Davalli, MD; Carmela Coppola, MD; Giovanni Esposito, MD; Mariolina V. Carriero, MD; Antonio Rapacciuolo, MD; Emilio Di Lorenzo, MD; Eugenio Stabile, MD; Cinzia Perrino, MD; Alaide Chieffo, MD; Francesco Pardo, MD; Massimo Chiariello, MD

From the Division of Cardiology (D.T., L.C., C.C., A.R., E.D., E.S., C.P., A.C., M.C.) and the Division of Internal Medicine (F.P.), University Federico II, and the National Cancer Institute (M.V.C.), Naples; Magna Graecia University, Catanzaro (C.I.); and the Unit of Metabolic Disease, Istituto Scientifico San Raffaele, Milan (A.D.), Italy; and the Department of Medicine, Duke University, Durham, NC (G.E.). The first 2 authors contributed equally to this study.

Correspondence to Ciro Indolfi, MD, FACC, FESC, Laboratory of Clinical and Experimental Interventional Cardiology, Federico II University, Via Sergio Pansini, 5, 80131 Naples, Italy. E-mail indolfi{at}unina.it

	Abstract

Top Abstract Introduction Methods Results Discussion References

 
Background—The mechanisms of increased neointimal hyperplasia after coronary interventions in diabetic patients are still unknown.

Methods and Results—Glucose and insulin effects on in vitro vascular smooth muscle cell (VSMC) proliferation and migration were assessed. The effect of balloon injury on neointimal hyperplasia was studied in streptozotocin-induced diabetic rats with or without adjunct insulin therapy. To study the effect of balloon injury in nondiabetic rats with hyperinsulinemia, pancreatic islets were transplanted under the kidney capsule in normal rats. Glucose did not increase VSMC proliferation and migration in vitro. In contrast, insulin induced a significant increase in VSMC proliferation and migration in cell cultures. Furthermore, in VSMC culture, insulin increased MAPK activation. A reduction in neointimal hyperplasia was consistently documented after vascular injury in hyperglycemic streptozotocin-induced diabetic rats. Insulin therapy significantly increased neointimal hyperplasia in these rats. This effect of hyperinsulinemia was totally abolished by transfection on the arterial wall of the N17H-ras–negative mutant gene. Finally, after experimental balloon angioplasty in hyperinsulinemic nondiabetic islet-transplanted rats, a significant increase in neointimal hyperplasia was observed.

Conclusions—In rats with streptozotocin-induced diabetes, balloon injury was not associated with an increase in neointimal formation. Exogenous insulin administration in diabetic rats and islet transplantation in nondiabetic rats increased both blood insulin levels and neointimal hyperplasia after balloon injury. Hyperinsulinemia through activation of the ras/MAPK pathway, rather than hyperglycemia per se, seems to be of crucial importance in determining the exaggerated neointimal hyperplasia after balloon angioplasty in diabetic animals.

Key Words: diabetes mellitus • balloon • angioplasty • insulin

	Introduction

Top Abstract Introduction Methods Results Discussion References

 
Diabetes mellitus is a poor prognostic factor for all patients with coronary artery disease and specifically for those who undergo CABG or balloon angioplasty.^{1 2 3} It is also well recognized that restenosis rates may be very high, varying from 49% to 71% among diabetic patients.^{1 2 3 4 5}

In addition, patients with diabetes mellitus and multivessel coronary disease were found to have a significantly higher mortality rate with PTCA than with CABG.^{1 2 3 4 5 6}

Extensive data are not yet available on coronary stents in patients with diabetes, but the use of internal mammary arteries with bypass grafting seems to be preferred, especially in patients with multivessel disease.^{7 8 9}

Serial intravascular ultrasound analysis showed that the main mechanism for increased restenosis in diabetic patients was an exaggerated intimal hyperplasia both in the presence and in the absence of stent deployment.¹⁰ In addition, the molecular mechanisms underlying this exaggerated vascular smooth muscle cell (VSMC) proliferation and the relative role of hyperglycemia versus hyperinsulinemia in promoting a greater restenosis after angioplasty or stenting have not yet been investigated.

Therefore, the aims of the present study were to assess (1) the effects of glucose and insulin on VSMC proliferation and migration in vitro, (2) response to balloon injury in rats with streptozotocin (STZ)-induced diabetes with or without adjunct insulin therapy, and (3) neointimal hyperplasia after vascular injury in nondiabetic rats with hyperinsulinemia after pancreatic islet transplantation.

	Methods

Top Abstract Introduction Methods Results Discussion References

 
VSMC Proliferation In Vitro
To assess the effects of glucose and insulin, 29.5x10⁴ VSMCs (A10, thoracic rat aorta) were plated and grown in DMEM/10% FCS in the presence of low (5.6 mmol/L), medium (14 mmol/L), and high (22.2 mmol/L) glucose or in the presence of different insulin concentrations (2, 20, and 200 nmol/L) or in the absence of the same (control). To evaluate glucose osmotic effects on VSMC proliferation, we included an additional control with an osmotically active nonmetabolized agent, sorbitol, at the same glucose concentrations. Cell numbers in all conditions were assessed every 48 hours for 6 days.

Mitogen-Activated Protein Kinase Assay
To assess the effect of insulin on the activation of the ras/MAPKK pathway, VSMCs were starved in DMEM/0.5% FCS for 48 hours. Then they were stimulated by different concentrations of insulin (2, 20, and 200 nmol/L) for 10 minutes. After this time, VSMCs were processed for mitogen-activated protein kinase (MAPK) assay, as previously described.¹¹

VSMC Migration Assay
VSMC migration was assayed by a modification of the Boyden’s chamber method as previously described.¹² VSMCs (20x10³) were placed in the upper chamber, and 25 µL of serum-free medium containing a migration factor such as N-formyl-methionyl-leucyl-phenylalanine (FMLP) or insulin or glucose was placed in the lower chamber. At the end of the assay period, VSMCs that had migrated to the lower side of the filter were counted under a microscope (x100) to quantify VSMC migration. Migration activity was expressed as the mean number of cells that had migrated per high-power field.

Animal Model of Diabetes
Animals in this study were handled according to the animal welfare regulation of Federico II University of Naples, and the protocol was approved by the animal use committee of this institution in accordance with the animal use principles of the American Society of Physiology.

Fifty Wistar rats (Charles River, Calco, Italy) were treated at 14 weeks of age with a single intraperitoneal injection of 100 mg/kg STZ (Sigma) in 0.05 mol/L citrate buffer. This model resembles insulin-dependent diabetes mellitus (IDDM) as previously described.¹³

The diabetic state was assessed starting the day after STZ injection by measurements of nonfasting plasma glucose concentration with a portable glucose meter (One Touch II; Johnson & Johnson). Only animals with plasma glucose concentrations >300 mg/dL were considered diabetics and were included in the present study.

Rat Islet Isolation and Transplantation
To obtain a rat model of hyperinsulinemia without diabetes, in 14 Fisher rats (Charles River, Calco, Italy) at 10 weeks after birth, pancreatic islets were transplanted under the kidney capsule by 1 investigator (A.D.) as previously described.¹⁴

Experimental Angioplasty Technique
Angioplasty of the carotid artery was performed as previously described and validated in our laboratory.^{15 16 17 18}

Study Design
Protocol I
The animals with STZ-induced diabetes were randomized before balloon injury into 2 groups: STZ group (n=11) and STZ+INS group (n=11, with insulin therapy).

Protocol II
Balloon injury was performed at 14 weeks after birth in hyperinsulinemic nondiabetic rats after islet transplantation (Transp Hyperins group).

Protocol III
In 12 rats with STZ-induced diabetes treated with insulin, we evaluated the effects of the in vivo inhibition of cellular ras using a negative mutant gene (N17H-ras) at the moment of the balloon injury (STZ/INS/ras group) as previously described.¹⁶

Insulin Administration
In the STZ+INS and in STZ/INS/ras groups, the day after STZ injection and for the following 14 days, insulin (Monotard, Novo Nordisk) was administered twice a day, from 4 to 8 IU according to plasma glucose level determined every day by use of the One Touch system. Balloon injury was performed 48 hours after STZ in the STZ+INS and STZ/INS/ras groups; thus, insulin was administered for a total of 16 days in both groups.

Blood Glucose and Insulin Levels
Blood samples from the tail vein were taken at the time of balloon injury and when carotid arteries were removed. These samples were analyzed for levels of glycemia and insulinemia. Plasma glucose was determined with the One Touch system. Insulin concentration was determined with a double-antibody radioimmunoassay using guinea pig anti-rat insulin serum, a rat insulin standard, and ¹²⁵I-labeled insulin (Linco Research).

Statistical Analysis
All data are shown as mean±SEM. Statistical analysis between groups was performed by 1-way ANOVA with an SPSS 10.0 program. When a significant overall effect was detected, Tukey’s test was applied to compare single mean values. A value of P<0.05 was considered significant.

	Results

Top Abstract Introduction Methods Results Discussion References

 
Effects of Glucose and Insulin on VSMC Proliferation In Vitro
Figure 1a shows that high glucose concentration markedly inhibited VSMC proliferation. We observed similar results in an additional control with an osmotically active nonmetabolized agent, sorbitol, at the same glucose concentrations (Figure 1b). In contrast, insulin increased VSMC proliferation in a dose-dependent manner (Figure 2a).

View larger version (18K): [in this window] [in a new window]   Figure 1. a, Effects of low (5.6 mmol/L), medium (14 mmol/L), and high (22.2 mmol/L) glucose concentrations on VSMC growth. Glucose at different concentrations (except for low) induced evident inhibition of VSMC proliferation vs control. Proliferation activities are mean±SD of 10 measurements. *P<0.001 vs CON. b, Effects of sorbitol at concentrations of 5.6, 14, and 22.2 mmol/L on VSMC growth. Sorbitol induced evident inhibition of VSMC proliferation vs control. Proliferation activities are mean±SD of 10 measurements. *P<0.001 vs CON.

View larger version (18K): [in this window] [in a new window]   Figure 2. a, Effects of increased concentrations of insulin (2, 20, 200 nmol/L) on VSMC growth. Insulin induced evident dose-dependent increase of VSMC proliferation vs control. Effect is significant even at low concentration of 2 nmol/L. Proliferation activities are mean±SD of 10 measurements. #P<0.05 vs CON; *P<0.001 vs CON. b, MAPK assays showing effect of insulin on MAPK activation. Insulin increased MAPK activation, as demonstrated by increase in ERK activation, at all concentrations. Only at highest concentrations did insulin weakly activate JNK and produce evident increase on P38 activation.

Effects of Insulin on the Activation of the ras/MAPK Pathway
Insulin increased ras/MAPK activation, as demonstrated by the increase in extracellular signal–regulated kinase (ERK) activation at all insulin concentrations (Figure 2b). Only at nonphysiological concentration did insulin weakly activate c-Jun NH2-terminal kinase (JNK) and produce an evident increase of P38 activation (Figure 2b). These data suggest that ERK downstream ras is the principal intracellular target of the action of insulin on VSMCs.

Effects of Glucose and Insulin on VSMC Migration In Vitro
Figure 3 shows that insulin significantly increased VSMC migration in a dose-dependent manner (Figure 3a). In contrast, cultured VSMCs were unaffected by glucose (Figure 3b).

View larger version (19K): [in this window] [in a new window]   Figure 3. a, Effects of glucose on VSMC migration vs FMLP. Neither low nor high glucose concentrations affected VSMC migration vs control and FMLP. Migration activities are expressed as number of cells per high-power field (HPF) and are mean±SD of 10 measurements. *P<0.01 vs all. b, Effects of insulin (2, 200 nmol/L) on VSMC migration vs FMLP. Insulin increased VSMC migration vs control and FMLP. Effect is significant even at low concentration of 2 nmol/L. Migration activities are expressed as number of cells per HPF and are mean±SD of 10 measurements. *P<0.01 vs CON; #P<0.001 vs CON, FMLP.

Effects of Vascular Injury on Neointimal Hyperplasia in Rats With STZ-Induced Diabetes (Protocol I)
After STZ injection, a 30% mortality was observed. A reproducible neointimal formation was found 14 days after balloon injury in the control group (CON group, n=12; neointima 0.113±0.026 mm²; neointima/media ratio 1.123±0.229) (Figures 4 and 5). Surprisingly, in animals treated with STZ (STZ group, n=9), we observed a significant reduction of both neointimal area and neointima/media ratio (neointima 0.070±0.029 mm², P<0.001 versus CON; neointima/media ratio 0.508±0.201, P<0.001 versus CON) (Figures 4 and 5). After balloon injury, we had a 20% mortality in rats of the control group and in rats with STZ-induced diabetes.

View larger version (18K): [in this window] [in a new window]   Figure 4. a, Bars represent neointimal cross-sectional area of common carotid arteries after balloon injury from rats subjected to only balloon injury (CON), rats treated with STZ), insulin-treated STZ-induced diabetic rats (STZ+INS), hyperinsulinemic nondiabetic islet-transplanted rats (Transp Hyperins), and insulin-treated rats with STZ-induced diabetes with transfection of ras-negative mutant gene (STZ+INS/ras-). *P<0.001 vs CON; #P<0.05 vs CON; P<0.001 vs STZ+INS and Transp Hyperins. b, Bars represent neointima/media ratio of common carotid arteries after balloon injury from each group of animals studied. *P<0.001 vs CON; P<0.001 vs STZ+INS and Transp Hyperins.

View larger version (75K): [in this window] [in a new window]   Figure 5. Representative hematoxylin-eosin–stained histological sections of common carotid arteries after balloon injury from each group of animals studied (abbreviations as in Figure 4).

Effect of Vascular Injury on Neointimal Hyperplasia in STZ-Induced Diabetic Rats With Insulin Therapy (Protocol I)
After balloon injury in animals with insulin-treated STZ-induced diabetes (STZ+INS group, n=9), we observed a significant increase of both neointimal area and neointima/media ratio (neointima 0.217±0.036 mm², P<0.001 versus CON; neointima/media ratio 1.722±0.364, P<0.001 versus CON) (Figures 4 and 5).

Effect of Islet Transplantation on Neointimal Hyperplasia After Vascular Injury (Protocol II)
In nondiabetic animals with hyperinsulinemia after islet transplantation (Transp Hyperins, n=5), we detected a significant increase of both neointimal area and neointima/media ratio after balloon injury (neointima 0.147±0.009 mm², P<0.05 versus CON; neointima/media ratio 1.545±0.082, P<0.001 versus CON) (Figures 4 and 5). In these animals, a 30% mortality after balloon injury was observed.

Effect of ras Inhibition on Neointimal Hyperplasia After Vascular Injury in Rats With STZ-Induced Diabetes (Protocol III)
In an additional 12 rats with STZ-induced diabetes under insulin therapy, the transfection on the vascular wall of a ras-negative mutant gene (N17H-ras) at the moment of the balloon injury (STZ/INS/ras group, n=9) caused a significant reduction of both neointimal area and neointima/media ratio compared with both the CON and the STZ+INS groups (neointima 0.069±0.018 mm², P<0.001 versus CON and STZ+INS; neointima/media ratio 0.539±0.114, P<0.001 versus CON and STZ+INS) (Figures 4 and 5).

Blood Glucose and Insulin Levels
Control rats (CON group) had a glycemia of 144±19.3 mg/dL and an insulinemia of 67.2±8.6 µU/mL (Figure 6). STZ-induced diabetic rats without insulin therapy showed a significant increase of plasma glucose levels (STZ group, glycemia 428.3±47.6 mg/dL, P<0.001 versus CON) and a significant reduction of insulin blood levels (STZ group, insulinemia 36.8±3.7 µU/mL, P<0.001 versus CON) (Figure 6). Insulin therapy reduced glycemia in the STZ+INS group (glycemia 266.7±18.2 mg/dL, P<0.001 versus STZ), with a significant increase in insulin levels (insulinemia 136.8±9.1 µU/mL, P<0.01 versus CON) (Figure 6). Furthermore, rats with transplants had a slight but significant reduction of glycemia (Transp Hyperins group, glycemia 98.2±5 mg/dL, P<0.05 versus CON) and a significant increase in blood insulin levels (Transp Hyperins group, insulinemia 133.1±3.6 µU/mL, P<0.001 versus CON) (Figure 6). Finally, also in the STZ/INS/ras group, insulin therapy reduced glycemia (glycemia 231.0±16.2 mg/dL, P<0.001 versus STZ), with a significant increase in insulin level (insulinemia 138.0±14.6 µU/mL, P<0.01 versus CON) (Figure 6).

View larger version (20K): [in this window] [in a new window]   Figure 6. a, Bars represent plasma glucose levels from each group of animals studied. Abbreviations as in Figure 4. *P<0.001 vs CON; #P<0.01 vs STZ; P<0.05 vs CON; P<0.01 vs CON. b, Bars represent insulin levels from each group of animals studied. *P<0.001 vs CON; #P<0.001 vs all.

	Discussion

Top Abstract Introduction Methods Results Discussion References

 
The major findings of the present study are that (1) hyperglycemia per se does not seem to be sufficient to induce an increased neointimal formation after balloon injury, which in hyperglycemic STZ-induced diabetic rats actually decreased; and (2) hyperinsulinemia plays a major role in determining the exaggerated neointimal hyperplasia after vascular injury in rats; ERK downstream ras is the principal intracellular target of the insulin actions on VSMCs.

Role of Hyperglycemia on VSMCs In Vitro and In Vivo
Although hyperglycemia may increase the expression of several growth factors, such as platelet-derived growth factor, and their effects on VSMC growth,^{12 19} our data demonstrated that high glucose concentrations alone did not affect VSMC migration and decreased VSMC proliferation in vitro (the 2 main mechanisms responsible for neointima formation after balloon injury). Glucose effects were entirely nonspecific to glucose metabolism as an inhibition of cell migration, and proliferation was also obtained with an osmotically active nonmetabolized agent, sorbitol. Therefore, we can simply speculate that glucose effects on VSMC growth in vitro seem to be related to an osmotic action.

Our in vivo data consistently demonstrated a significant reduction in neointimal thickness after experimental angioplasty in hyperglycemic rats with STZ-induced diabetes, although the glucose levels were 400 to 500 mg/dL. Recent data have also shown that in rabbits with alloxan-induced diabetes, high glucose levels were associated with reduced neointimal hyperplasia after balloon injury.²⁰ This effect was probably due to improved endothelial cell regrowth.²⁰

Role of Hyperinsulinemia on VSMCs In Vitro and on Neointimal Hyperplasia After Balloon Injury In Vivo
High circulating insulin levels were associated with an increased risk for coronary artery diseases.^{21 22} It has also been hypothesized, but never proved, that hyperinsulinemia in non–insulin-dependent diabetes mellitus (NIDDM) exerts a detrimental effect on injured vessels and underlies the high mortality in diabetic patients²³ after percutaneous transluminal coronary angioplasty. Likewise, hyperinsulinemia in nondiabetic patients seems to be a good predictor of restenosis after coronary stenting.²⁴ Furthermore, it has also been suggested that increased levels of plasminogen activator inhibitor type 1 secondary to high insulin levels are likely to mediate the adverse effects of insulin on vessel wall.²⁵ The BARI trial showed an increased mortality only in patients who were treated with oral hypoglycemic agents or insulin.¹ These observations imply that higher insulin levels in these patients underlie the adverse outcome after angioplasty.¹ Moreover, atherosclerosis-like lesions were documented when long-term insulin injections were performed in rats.²⁶ In addition, the intensive treatment of diabetes with insulin was not associated with a reduction in the occurrence of coronary artery disease in either the DCCT trial²⁷ or the UKPDS Study.²⁸

In many NIDDM patients, insulin levels are higher than those in nondiabetic subjects.²³ In the presence of insulin resistance, when the metabolic action of insulin is ineffective, the proliferative response to hyperinsulinemia may still occur.²³

In IDDM, insulin therapy is delivered in nonphysiological ways with respect to route and control of delivery. Thus, in many patients with IDDM, tissues may be exposed to higher levels of insulin than in those without diabetes.

VSMC migration and proliferation play a major role in the pathogenesis of restenosis in diabetic patients. Our data demonstrated that insulin increases VSMC migration and proliferation. The primary physiological substrate of the insulin receptor tyrosine kinase is a protein called insulin receptor substrate-1 (IRS-1). IRS-1 is associated with the adaptor protein GRB-2, which links IRS-1 to the ras-raf-MAPK cascade, which is the central pathway for VSMC growth. Insulin increases the amount of farnesylated p21ras in VSMCs.²⁹ Furthermore, recent data demonstrated increased amounts of farnesylated p21ras in tissues of hyperinsulinemic animals.²⁹ Finally, our laboratory previously demonstrated that the inhibition of ras or MAPK genes prevented neointimal formation after balloon angioplasty in rats.^{16 18 30 31}

The role of hyperinsulinemia in promoting restenosis, however, is still a controversial issue.^{32 33 34} The diabetic state affects different stages of the restenotic process.³² In fact, it has been suggested that many of the potential mechanisms promoting restenosis in diabetic patients correlate with hyperglycemia rather than hyperinsulinemia.^{32 33}

A recent study demonstrated an association between MAPK activity and VSMC proliferation after vascular injury in diabetic rabbits independent of insulin-like growth factor-1.³⁵ In agreement with these data, we have demonstrated that insulin increased MAPK activation; furthermore, we have also shown that ERK downstream ras is the principal intracellular target of the insulin actions on VSMCs. Nevertheless, it should be pointed out that the insulin concentrations used in our study were clearly much higher than those encountered in vivo, but this is not surprising, because such high concentrations are required in view of the known differences between rodents and humans.

Our in vivo data demonstrated that insulin therapy in diabetic rats reduced plasma glucose levels at the expense of a significant increase in insulin blood levels. This increase in insulin blood levels was associated with the exaggerated neointimal hyperplasia observed after balloon injury.

To increase the insulin levels in nondiabetic rats and to obtain a model of hyperinsulinemia as the only risk factor for exaggerated neointimal hyperplasia, we performed an additional protocol in which pancreatic islets were transplanted in normal nondiabetic animals under the kidney capsule.¹⁴ In this group, we observed an increase of insulin blood levels similar to that in STZ-induced diabetic rats with insulin therapy. In these animals, we also observed an exaggerated neointimal formation after experimental balloon angioplasty.

Finally, in hyperinsulinemic STZ-induced diabetic rats, the transfection of a ras-negative mutant gene reduced neointimal hyperplasia after balloon injury.

Taken together, these data further support the hypothesis that hyperinsulinemia, by increasing ras/MAPK pathway activation, is the main mechanism responsible for the greater rate of restenosis observed in diabetic patients.

Animal Models and Limitations of the Study
STZ administered to mature rats induces severe and permanent diabetes, with a decrease in insulin levels, to produce a cytotoxic model of diabetes very similar to IDDM.¹³

To further rule out a possible acute effect of STZ per se on VSMC proliferation in vivo, we also performed experiments in rats that had been rendered diabetic by STZ in the neonatal period (3 days after birth). In this same group of hyperglycemic and insulinopenic animals, the injury was performed at 14 weeks after birth, and we observed the same effects of balloon injury on neointimal hyperplasia as in the adult model of STZ-induced diabetes (data not shown).

Clinical adverse experience in subjects with diabetes undergoing coronary interventions is encountered predominantly in patients with type 2 diabetes because of the much higher prevalence of type 2 (accounting for >90% of diabetic patients) than type 1 diabetes. For this reason, caution should be used in extrapolating the present results in a clinical setting. Because of the greater duration of the disease, however, patients with IDDM risk higher cardiovascular morbidity and mortality than those with NIDDM. Furthermore, because of their insulin-requiring state, IDDM patients are exposed for a longer period to the potentially detrimental effects of insulin.

To obtain a rat model of hyperinsulinemia without diabetes, we used a standard technique to transplant pancreatic islets under the kidney capsule in nondiabetic rats.¹⁴ This allowed us to have hyperinsulinemia as a single potential factor promoting neointimal hyperplasia after balloon angioplasty.

Finally, in the present study, the blood samples to assess glucose and insulin levels were obtained in anesthetized animals. It is likely that slightly different results could be obtained in conscious animals.

Clinical Relevance of the Study
Our experimental data support the hypothesis that rigorous glycemic control alone may not be sufficient to reduce the rate of restenosis in diabetic patients. Rather, hyperinsulinemia is responsible for the exaggerated neointimal proliferation observed in our animal models and could explain the increased restenosis rate observed after interventional procedures in diabetic patients. Therefore, it should be pointed out that in diabetic patients who require insulin therapy, good control of blood glucose should be obtained with the lowest possible levels of circulating insulin.

Further clinical trials are needed, however, to evaluate the impact of both hyperinsulinemia and tight glycemic control on the rate of restenosis after balloon angioplasty and coronary stenting in diabetic patients.

	Acknowledgments

 
We thank Armando Coppola for excellent technical assistance.

Received November 3, 2000; revision received February 12, 2001; accepted February 16, 2001.

	References

Top Abstract Introduction Methods Results Discussion References

 
1. The Bypass Angioplasty Revascularization Investigation (BARI) Investigators. Comparison of coronary bypass surgery with angioplasty in patients with multivessel disease. N Engl J Med. 1996;335:217–225.[Abstract/Free Full Text]

2. CABRI Trial Participants. First-year results of CABRI (Coronary Angioplasty versus Bypass Revascularisation Investigation). Lancet. 1995;346:1179–1184.[Medline] [Order article via Infotrieve]

3. Chiariello M, Indolfi C. Silent myocardial ischemia in patients with diabetes mellitus. Circulation. 1996;93:2089–2091.[Free Full Text]

4. Investigators of the NHLBI PTCA Registry, Kip KE, Faxon DP, Detre KM, et al. Coronary angioplasty in diabetic patients. The National Heart, Lung, and Blood Institute Percutaneous Transluminal Coronary Angioplasty Registry. Circulation. 1996;94:1818–1825.[Abstract/Free Full Text]

5. Van Belle E, Bauters C, Hubert E, et al. Restenosis rates in diabetic patients: a comparison of coronary stenting and balloon angioplasty in native coronary vessels. Circulation. 1997;96:1454–1460.[Abstract/Free Full Text]

6. Weintraub WS, Stein B, Kosinski A, et al. Outcome of coronary bypass surgery versus coronary angioplasty in diabetic patients with multivessel coronary artery disease. J Am Coll Cardiol. 1998;31:10–19.[Abstract/Free Full Text]

7. Carrozza JP, Kuntz RE, Fishmann RF, et al. Restenosis after arterial injury caused by coronary stenting in patients with diabetes mellitus. Ann Intern Med. 1993;118:344–349.[Abstract/Free Full Text]

8. Grundy SM, Benjamin IJ, Burke GL, et al. Diabetes and cardiovascular disease: a statement for healthcare professionals from the American Heart Association. Circulation. 1999;100:1134–1146.[Free Full Text]

9. Friesinger GC II, Gavin JA III. Diabetes and the cardiologists: a call to action. J Am Coll Cardiol. 2000;35:1130–1133.[Free Full Text]

10. Kornowski R, Mintz GS, Kent KM, et al. Increased restenosis in diabetes mellitus after coronary interventions is due to exaggerated intimal hyperplasia. Circulation. 1997;95:1366–1369.[Abstract/Free Full Text]

11. Esposito G, Naga Prasad SA, Rapacciuolo A, et al. Cardiac overexpression of a G_q inhibitor blocks the induction of extracellular signal–regulated kinase and c-Jun NH₂-terminal kinase activity in in vivo pressure overload. Circulation. 2001;103:1453–1458.

12. Yasunari K, Kohno M, Kano H, et al. Antioxidants improve impaired insulin-mediated glucose uptake and prevent migration and proliferation of cultured rabbit aortic coronary smooth muscle cells induced by high glucose. Circulation. 1999;99:1370–1378.[Abstract/Free Full Text]

13. Portha B, Levacher C, Picon L, et al. Diabetogenic effect of streptozotocin in the rat during the perinatal period. Diabetes. 1974;23:889–895.[Medline] [Order article via Infotrieve]

14. Napoli R, Davalli AM, Hirshmann F, et al. Islet transplantation under the kidney capsule fully corrects the impaired skeletal muscle glucose transport system of streptozotocin diabetic rats. J Clin Invest. 1996;97:1389–1397.[Medline] [Order article via Infotrieve]

15. Indolfi C, Esposito G, Di Lorenzo E, et al. Smooth muscle cell proliferation is proportional to the degree of balloon injury in a rat model of angioplasty. Circulation. 1995;92:1230–1235.[Abstract/Free Full Text]

16. Indolfi C, Avvedimento EV, Rapacciuolo A, et al. Inhibition of cellular ras prevents smooth muscle cell proliferation after vascular injury in vivo. Nat Med. 1995;1:541–545.[Medline] [Order article via Infotrieve]

17. Indolfi C, Avvedimento EV, Di Lorenzo E, et al. Activation of cAMP-PKA signaling in vivo inhibits smooth muscle cell proliferation induced by vascular injury. Nat Med. 1997;3:775–779.[Medline] [Order article via Infotrieve]

18. Indolfi C, Avvedimento EV, Rapacciuolo A, et al. In vivo gene transfer: prevention of neointima formation by inhibition of mitogen activated protein kinase kinase. Basic Res Cardiol. 1997;92:378–384.[Medline] [Order article via Infotrieve]

19. McClain DA, Paterson AJ, Roos MD, et al. Glucose and glucosamine regulate growth factor gene expression in vascular smooth muscle cells. Proc Natl Acad Sci U S A. 1992;89:8150–8154.[Abstract/Free Full Text]

20. Schiller NK, Timothy AM, Chen IL, et al. Endothelial cell regrowth and morphology after balloon catheter injury of alloxan-induced diabetic rabbits. Am J Physiol. 1999;277:H740–H748.[Abstract/Free Full Text]

21. Reaven GM, Laws A. Insulin resistance, compensatory hyperinsulinemia, and coronary heart disease. Diabetologia. 1994;37:948–952.[Medline] [Order article via Infotrieve]

22. Lempiainen P, Mykkanen L, Pyorala K, et al. Insulin resistance syndrome predicts coronary heart disease events in elderly nondiabetic men. Circulation. 1999;100:123–128.[Abstract/Free Full Text]

23. Stout RW. Insulin and atheroma: 20-yr perspective. Diabetes Care. 1990;13:631–654.[Abstract]

24. Osanai H, Kanayama H, Miyazaki Y, et al. Usefulness of enhanced insulin secretion during an oral glucose tolerance test as a predictor of restenosis after direct percutaneous transluminal coronary angioplasty during acute myocardial infarction in patients without diabetes mellitus. Am J Cardiol. 1998;81:698–701.[Medline] [Order article via Infotrieve]

25. Sobel BE. Potentiation of vasculopathy by insulin: implications from an NHLBI alert. Circulation. 1996;93:1613–1615.[Free Full Text]

26. Sato Y, Shiraishi S, Oshida Y, et al. Experimental atherosclerosis-like lesions induced by hyperinsulinism in Wistar rats. Diabetes. 1989;38:91–96.[Abstract]

27. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993;329:977–986.[Abstract/Free Full Text]

28. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352:837–853.[Medline] [Order article via Infotrieve]

29. Goalstone ML, Wall K, Leitner JW, et al. Increased amounts of farnesylated p21Ras in tissues of hyperinsulinemic animals. Diabetologia. 1999;42:310–316.[Medline] [Order article via Infotrieve]

30. Indolfi C, Chiariello M, Avvedimento EV. Selective gene therapy for proliferative disorders: sense and antisense. Nat Med. 1996;2:634–635.[Medline] [Order article via Infotrieve]

31. Indolfi C, Coppola C, Torella D, et al. Gene therapy for restenosis after balloon angioplasty and stenting. Cardiol Rev. 1999;7:324–331.[Medline] [Order article via Infotrieve]

32. Aronson D, Bloomgarden Z, Rayfield EJ. Potential mechanisms promoting restenosis in diabetic patients. J Am Coll Cardiol. 1996;27:528–535.[Abstract]

33. Aronson D. Restenosis in diabetic patients: is hyperinsulinemia the culprit? Circulation. 1996;94:3003–3004. Letter.

34. Sobel BE. Restenosis in diabetic patients: is hyperinsulinemia the culprit? Circulation. 1996;94:3004–3005. Response.

35. Schiller NK, McNamara DB. Balloon catheter vascular injury of the alloxan-induced diabetic rabbit: the role of insulin-like growth factor-1. Mol Cell Biochem. 1999;202:159–167. [Medline] [Order article via Infotrieve]

This article has been cited by other articles:

				S. Wang and Y. Li Expression of constitutively active cGMP-dependent protein kinase inhibits glucose-induced vascular smooth muscle cell proliferation Am J Physiol Heart Circ Physiol, December 1, 2009; 297(6): H2075 - H2083. [Abstract] [Full Text] [PDF]

				D. M. Breen, K. K. Chan, J. K. Dhaliwall, M. R. Ward, N. Al Koudsi, L. Lam, M. De Souza, H. Ghanim, P. Dandona, D. J. Stewart, et al. Insulin Increases Reendothelialization and Inhibits Cell Migration and Neointimal Growth After Arterial Injury Arterioscler Thromb Vasc Biol, July 1, 2009; 29(7): 1060 - 1066. [Abstract] [Full Text] [PDF]

				Q. Pu, Y. Chang, C. Zhang, Y. Cai, and A. Hassid Chronic insulin treatment suppresses PTP1B function, induces increased PDGF signaling, and amplifies neointima formation in the balloon-injured rat artery Am J Physiol Heart Circ Physiol, January 1, 2009; 296(1): H132 - H139. [Abstract] [Full Text] [PDF]

				D. Zhuang, Q. Pu, B. Ceacareanu, Y. Chang, M. Dixit, and A. Hassid Chronic insulin treatment amplifies PDGF-induced motility in differentiated aortic smooth muscle cells by suppressing the expression and function of PTP1B Am J Physiol Heart Circ Physiol, July 1, 2008; 295(1): H163 - H173. [Abstract] [Full Text] [PDF]

				N. Sasaki, T. Yamashita, T. Takaya, M. Shinohara, R. Shiraki, M. Takeda, N. Emoto, A. Fukatsu, T. Hayashi, K. Ikemoto, et al. Augmentation of Vascular Remodeling by Uncoupled Endothelial Nitric Oxide Synthase in a Mouse Model of Diabetes Mellitus Arterioscler Thromb Vasc Biol, June 1, 2008; 28(6): 1068 - 1076. [Abstract] [Full Text] [PDF]

				F. Anan, T. Masaki, Y. Umeno, T. Iwao, H. Yonemochi, N. Eshima, T. Saikawa, and H. Yoshimatsu Correlations of high-sensitivity C-reactive protein and atherosclerosis in Japanese type 2 diabetic patients Eur. J. Endocrinol., September 1, 2007; 157(3): 311 - 317. [Abstract] [Full Text] [PDF]

				D. Torella, A. Curcio, C. Gasparri, V. Galuppo, D. D. Serio, F. C. Surace, A. L. Cavaliere, A. Leone, C. Coppola, G. M. Ellison, et al. Fludarabine prevents smooth muscle proliferation in vitro and neointimal hyperplasia in vivo through specific inhibition of STAT-1 activation Am J Physiol Heart Circ Physiol, June 1, 2007; 292(6): H2935 - H2943. [Abstract] [Full Text] [PDF]

				D. Bruemmer C-Peptide in Insulin Resistance and Vascular Complications: Teaching an Old Dog New Tricks Circ. Res., November 24, 2006; 99(11): 1149 - 1151. [Full Text] [PDF]

				S. Srivastava, K. V. Ramana, R. Tammali, S. K. Srivastava, and A. Bhatnagar Contribution of aldose reductase to diabetic hyperproliferation of vascular smooth muscle cells. Diabetes, April 1, 2006; 55(4): 901 - 910. [Abstract] [Full Text] [PDF]

				T. Matsuoka, J. Wada, I. Hashimoto, Y. Zhang, J. Eguchi, N. Ogawa, K. Shikata, Y. S. Kanwar, and H. Makino Gene Delivery of Tim44 Reduces Mitochondrial Superoxide Production and Ameliorates Neointimal Proliferation of Injured Carotid Artery in Diabetic Rats Diabetes, October 1, 2005; 54(10): 2882 - 2890. [Abstract] [Full Text] [PDF]

				M. Jonas, E. R. Edelman, A. Groothuis, A. B. Baker, P. Seifert, and C. Rogers Vascular Neointimal Formation and Signaling Pathway Activation in Response to Stent Injury in Insulin-Resistant and Diabetic Animals Circ. Res., September 30, 2005; 97(7): 725 - 733. [Abstract] [Full Text] [PDF]

				J. Molnar, S. Yu, N. Mzhavia, C. Pau, I. Chereshnev, and H. M. Dansky Diabetes Induces Endothelial Dysfunction but Does Not Increase Neointimal Formation in High-Fat Diet Fed C57BL/6J Mice Circ. Res., June 10, 2005; 96(11): 1178 - 1184. [Abstract] [Full Text] [PDF]

				P. Fiorina, C. Gremizzi, P. Maffi, R. Caldara, D. Tavano, L. Monti, C. Socci, F. Folli, F. Fazio, E. Astorri, et al. Islet Transplantation Is Associated With an Improvement of Cardiovascular Function in Type 1 Diabetic Kidney Transplant Patients Diabetes Care, June 1, 2005; 28(6): 1358 - 1365. [Abstract] [Full Text] [PDF]

				D. M. Sengstock, P. V. Vaitkevicius, and M. A. Supiano Arterial Stiffness Is Related to Insulin Resistance in Nondiabetic Hypertensive Older Adults J. Clin. Endocrinol. Metab., May 1, 2005; 90(5): 2823 - 2827. [Abstract] [Full Text] [PDF]

				T. Nakazawa, T. Chiba, E. Kaneko, K. Yui, M. Yoshida, and K. Shimokado Insulin Signaling in Arteries Prevents Smooth Muscle Apoptosis Arterioscler Thromb Vasc Biol, April 1, 2005; 25(4): 760 - 765. [Abstract] [Full Text] [PDF]

				D. Zhuang, A.-C. Ceacareanu, B. Ceacareanu, and A. Hassid Essential role of protein kinase G and decreased cytoplasmic Ca2+ levels in NO-induced inhibition of rat aortic smooth muscle cell motility Am J Physiol Heart Circ Physiol, April 1, 2005; 288(4): H1859 - H1866. [Abstract] [Full Text] [PDF]

				D. Torella, D. Leosco, C. Indolfi, A. Curcio, C. Coppola, G. M. Ellison, V. G. Russo, M. Torella, G. L. Volti, F. Rengo, et al. Aging exacerbates negative remodeling and impairs endothelial regeneration after balloon injury Am J Physiol Heart Circ Physiol, December 1, 2004; 287(6): H2850 - H2860. [Abstract] [Full Text] [PDF]

				D. Zhuang, A.-C. Ceacareanu, Y. Lin, B. Ceacareanu, M. Dixit, K. E. Chapman, C. M. Waters, G. N. Rao, and A. Hassid Nitric oxide attenuates insulin- or IGF-I-stimulated aortic smooth muscle cell motility by decreasing H2O2 levels: essential role of cGMP Am J Physiol Heart Circ Physiol, June 1, 2004; 286(6): H2103 - H2112. [Abstract] [Full Text] [PDF]

				A. Curcio, D. Torella, G. Cuda, C. Coppola, M. C. Faniello, F. Achille, V. G. Russo, M. Chiariello, and C. Indolfi Effect of stent coating alone on in vitro vascular smooth muscle cell proliferation and apoptosis Am J Physiol Heart Circ Physiol, March 1, 2004; 286(3): H902 - H908. [Abstract] [Full Text] [PDF]

				C. V. Desouza, S. N. Murthy, J. Diez, B. Dunne, A. S. Matta, V. A. Fonseca, and D. B. McNamara Differential Effects of Peroxisome Proliferator Activator Receptor-{alpha} and {gamma} Ligands on Intimal Hyperplasia After Balloon Catheter-Induced Vascular Injury in Zucker Rats Journal of Cardiovascular Pharmacology and Therapeutics, December 1, 2003; 8(4): 297 - 305. [Abstract] [PDF]

				M. Dixit, D. Zhuang, B. Ceacareanu, and A. Hassid Treatment With Insulin Uncovers the Motogenic Capacity of Nitric Oxide in Aortic Smooth Muscle Cells: Dependence on Gab1 and Gab1-SHP2 Association Circ. Res., November 14, 2003; 93 (10): e113 - e123. [Abstract] [Full Text] [PDF]

				Z. Zhou, K. Wang, M. S. Penn, S. P. Marso, M. A. Lauer, F. Forudi, X. Zhou, W. Qu, Y. Lu, D. M. Stern, et al. Receptor for AGE (RAGE) Mediates Neointimal Formation in Response to Arterial Injury Circulation, May 6, 2003; 107(17): 2238 - 2243. [Abstract] [Full Text] [PDF]

				C. Indolfi, D. Torella, C. Coppola, A. Curcio, F. Rodriguez, A. Bilancio, A. Leccia, O. Arcucci, M. Falco, D. Leosco, et al. Physical Training Increases eNOS Vascular Expression and Activity and Reduces Restenosis After Balloon Angioplasty or Arterial Stenting in Rats Circ. Res., December 13, 2002; 91(12): 1190 - 1197. [Abstract] [Full Text] [PDF]

				C. Indolfi, D. Torella, C. Coppola, E. Stabile, G. Esposito, A. Curcio, A. Pisani, L. Cavuto, O. Arcucci, M. Cireddu, et al. Rat carotid artery dilation by PTCA balloon catheter induces neointima formation in presence of IEL rupture Am J Physiol Heart Circ Physiol, August 1, 2002; 283(2): H760 - H767. [Abstract] [Full Text] [PDF]

				N. Sreejayan, Y. Lin, and A. Hassid NO Attenuates Insulin Signaling and Motility in Aortic Smooth Muscle Cells via Protein Tyrosine Phosphatase 1B-Mediated Mechanism Arterioscler Thromb Vasc Biol, July 1, 2002; 22(7): 1086 - 1092. [Abstract] [Full Text] [PDF]

				C. Indolfi Genetic factors in atherosclerosis: status and perspectives Eur. Heart J. Suppl., March 1, 2002; 4(suppl_B): B14 - B16. [Abstract] [PDF]

This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Indolfi, C. Articles by Chiariello, M. Search for Related Content PubMed PubMed Citation Articles by Indolfi, C. Articles by Chiariello, M. Related Collections Restenosis Cell signalling/signal transduction Smooth muscle proliferation and differentiation Type 1 diabetes Type 2 diabetes